Rapport Therapeutics, Inc. shares rise over 180.0%, currently trading at $40.01

Rapport Therapeutics, Inc. shares rise over 180.0%, currently trading at $40.01

Rapport Therapeutics, Inc. (RAPP) experienced a significant surge in its stock price, rising over 180.0% to $40.01 on September 2, 2025. This dramatic increase came following the company's announcement of promising results from its Phase 2a clinical trial of RAP-219, an investigational treatment for drug-resistant focal onset seizures [1][2][3].

The Phase 2a trial, which involved 30 patients, demonstrated statistically significant reductions in long seizure episodes (LEs) and clinical seizures compared to baseline over an 8-week treatment period. Specifically, 85.2% of patients achieved at least a 30% reduction in LEs, and 72.0% achieved at least a 50% reduction in clinical seizures [1]. Notably, 24% of participants achieved seizure freedom during the treatment period [1][2][3].

RAP-219 was generally well-tolerated, with most adverse events being mild or moderate in severity. The most frequently observed side effects included dizziness, headache, and fatigue [1][2][3].

Following these results, Rapport plans to advance RAP-219 into two Phase 3 pivotal trials in the third quarter of 2026. The company also expects to present additional efficacy analyses and 8-week follow-up results in 2026 [1][2]. Additionally, Rapport is developing a long-acting injectable (LAI) formulation of RAP-219 and is testing the therapy in a Phase 2 trial for bipolar mania, with topline results expected in the first half of 2027 [1][2][3].

The stock price surge reflects investors' enthusiasm for the trial results and the potential commercial success of RAP-219. Prior to the announcement, RAPP had been struggling with negative returns, showing a year-to-date decline of 19.05% and a one-year return of -32.33% as of September 5, 2025 [3]. The premarket surge to $34.99 represented a stunning 143.66% increase from Friday's closing price of $14.36, demonstrating investors' recognition of the drug's potential to address a substantial unmet medical need [3].

References:
[1] https://www.benzinga.com/news/health-care/25/09/47546412/rapport-reports-promising-epilepsy-study-outcomes-plans-phase-3-trials-next-year
[2] https://investorshub.advfn.com/market-news/article/15869/rapport-therapeutics-surges-after-promising-mid-stage-seizure-drug-trial
[3] https://tokenist.com/why-did-rapport-therapeutics-inc-shares-skyrocket-in-premarket/